MRK

Merck (MRK)

Merck and Co Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NYSE:MRK

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/29	22:10	IH Market News	Rising Treasury Yields May Weigh On Wall Street	NYSE:MRK	Merck and Co Inc
2024/05/29	20:34	IH Market News	Robinhood Shares Surge 3.3% on Stock Buyback Announcement; Anglo Declines BHP Deadline Extension, and More News	NYSE:MRK	Merck and Co Inc
2024/05/29	20:15	Business Wire	FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma	NYSE:MRK	Merck and Co Inc
2024/05/29	19:45	Business Wire	Merck to Acquire EyeBio	NYSE:MRK	Merck and Co Inc
2024/05/29	05:44	IH Market News	Nasdaq Climbs To Another Record Closing High But Dow Sees Further Downside	NYSE:MRK	Merck and Co Inc
2024/05/29	05:31	Edgar (US Regulatory)	Form SD - Specialized disclosure report	NYSE:MRK	Merck and Co Inc
2024/05/29	04:12	Business Wire	Merck Announces Third-Quarter 2024 Dividend	NYSE:MRK	Merck and Co Inc
2024/05/28	19:45	Business Wire	Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)	NYSE:MRK	Merck and Co Inc
2024/05/20	19:28	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NYSE:MRK	Merck and Co Inc
2024/05/17	05:15	Edgar (US Regulatory)	Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses	NYSE:MRK	Merck and Co Inc
2024/05/16	00:31	Edgar (US Regulatory)	Form POSASR - Post-effective Amendment to an automatic shelf registration statement	NYSE:MRK	Merck and Co Inc
2024/05/15	19:45	Business Wire	Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline	NYSE:MRK	Merck and Co Inc
2024/05/13	19:45	Business Wire	Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma	NYSE:MRK	Merck and Co Inc
2024/05/09	20:05	PR Newswire (Canada)	Santé Canada approuve KEYTRUDA® pour le traitement, en association avec une chimiothérapie à base de gemcitabine, des adultes atteints d'un carcinome des voies biliaires non résécable localement avancé ou métastatique	NYSE:MRK	Merck and Co Inc
2024/05/09	20:05	PR Newswire (Canada)	Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy	NYSE:MRK	Merck and Co Inc
2024/05/09	19:45	Business Wire	Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent	NYSE:MRK	Merck and Co Inc
2024/05/08	19:45	Business Wire	Merck to Participate in the Bank of America Securities 2024 Healthcare Conference	NYSE:MRK	Merck and Co Inc
2024/05/07	05:29	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NYSE:MRK	Merck and Co Inc
2024/05/07	05:10	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:MRK	Merck and Co Inc
2024/05/07	05:08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:MRK	Merck and Co Inc
2024/05/07	05:06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:MRK	Merck and Co Inc
2024/05/07	05:01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:MRK	Merck and Co Inc
2024/05/01	20:15	Business Wire	Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma	NYSE:MRK	Merck and Co Inc
2024/04/29	22:00	Business Wire	Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults	NYSE:MRK	Merck and Co Inc
2024/04/26	05:40	IH Market News	U.S. Stocks Climb Well Off Worst Levels But Close Mostly Lower	NYSE:MRK	Merck and Co Inc
2024/04/25	22:09	IH Market News	Futures Pointing To Sharply Lower Open On Wall Street	NYSE:MRK	Merck and Co Inc
2024/04/25	20:52	IH Market News	Southwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on Earnings	NYSE:MRK	Merck and Co Inc
2024/04/25	19:30	Business Wire	Merck Announces First-Quarter 2024 Financial Results	NYSE:MRK	Merck and Co Inc
2024/04/19	20:04	PR Newswire (Canada)	Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-conta	NYSE:MRK	Merck and Co Inc
2024/04/19	20:04	PR Newswire (Canada)	Santé Canada approuve KEYTRUDA® comme traitement de première intention, en association avec une chimiothérapie à base de fluoropyrimidine et de platine, des adultes atteints d'un adénocarcinome gastrique ou de la jonction gastro-œsophagienne (JGO) H	NYSE:MRK	Merck and Co Inc